Professional Documents
Culture Documents
Obstetrical DIC
De Lee 1901
Mrs H, 35 years of age, IV para, German At 2 AM of the 13th she awoke with a pain in the
abdomenshe sent for me about 7 and I arrived at 8:20 The pulse was full and bounding, but the patient was palethe uterusnow very hard, large, symmetrical, and tender. No heart tones Diagnosed premature detachment of the placentathe flow soon became profuse With the help of the husband alone I put her on the table and prepared the parts
De Lee 1901
gave a hypodermic of strychnine and a large,
bloody infiltration of the skin and subcutaneous tissue took place salt solution, one quart, was injectedDeep blue ecchymoses appeared around the puncture and extended up into the axilla, blood oozing persistantly from the hole and not to be stopped with plaster I tried to do a version, but the hands, tired with two hours hard operating, were paralyzed
De Lee 1901
Placenta was loose in the cavity, which was filled
with old, dark, firm, almost black clotsdark, thin, almost lake-coloured blood followed There was no atony here before we could retampon with gelatin gauze she became unconscious and died. It was three hours from the time I started and ten hours from the onset of first symptoms
De Lee 1901
Is there such a disease as acquired hemophilia? The causes of this are unknown; consanguinity of
marriage, tuberculosis, gout, maternal mental shock during gestation Does the loss of blood favor further hemorrhage per se?...the blood that is lost is light and watery, not dark I believethere is such an affection as a temporary hemophilia, but the demonstration of the same, I admit, presents no little difficulty
Objectives
Provide an overview of coagulation Describe the pathophysiology & etiology of DIC in
obstetrics
Discuss approach to treatment of DIC in pregnancy Review 30 years of obstetrical DIC in the IWK
Coagulation 101
PRIMARY HAEMOSTASIS
Coagulation
SECONDARY HAEMOSTASIS
Primary Haemostasis
Interaction between
Endothelium important
pathogenesis of DIC
Sepsis Preeclampsia Hypovolemic shock
Secondary Haemostasis
aPTT (Activated Partial Thromboplastin Time) Reflection of the intrinsic & common pathways
All factors except VII Normal 24.1 31.6 sec at IWK
(FDPs)
Do not discriminate between products of cross-linked fibrin and fibrinogen (limits specificity) Newer assays for cross-linked fibrin degradation products (Ddimers)
Many other conditions have D-dimers Trauma Recent surgery Venous thromboembolism Pregnancy
What is DIC?
SYSTEMIC THRO Bleeding MBOHE & M Clotting ORRHAGIC DISORDER SEEN IN ASSOCIATION WITH WELL-DEFINED CLINICAL SITUATIONS AND LABORATORY EVIDENCE OF:
1. 2. 3. 4.
Procoagulant activation Fibrinolytic activation Inhibitor consumption Biochemical evidence of end-organ damage or failure
Processes in DIC
Objective Approach
Multitude of tests with multiple variables affecting
results makes diagnosis confusing Analysis of 900 pts with DIC (non-pregnant)
Thrombocytopenia > Elevated FDP > prolonged PT > prolonged aPTT > low fibrinogen
Haemostasis (ISTH) developed a more objective scoring system for the diagnosis of DIC
Compared to blinded expert assessments for DIC, found to be 91% sensitive and 97% specific
No universally accepted definition of DIC Great spectrum of manifestations Normal pregnancy state is hypercoagulable
Letsky EA. Best Pract Res Clin Obs Gynecol (2001) 15: 623-44.
pregnancy
Marked shortening of PT and aPTT Consumption of coagulation factors may elevate the PT and aPTT but be still within normal non-pregnant ranges Important to assess serial changes in PT and aPTT
Similar problem with platelet count Fibrinogen levels can double in pregnancy Not all cases of DIC have low fibrinogen
Stage 2: Uncompensated As above plus: but no haemostatic Platelets Fibrinogen failure Factors V and VIII Stage 3: Rampant with haemostatic failure As above plus: Platelets Gross depletion of coagulation factors (particularly fibrinogen) FDPs
Thrombocytopenia
Feature of ~98% of DIC cases Platelet count <50 x 109 in ~50% Correlates to Thrombin generation
aPTT and PT
Prolonged in 50-75% of cases of DIC at some point in
Consumption of coagulation factors Abnormal synthesis in the liver Loss of proteins with massive bleeding
Times may actually be shortened initially (~50%) activated circulating clotting factors
Impair fibrin monomer polymerization (i.e. prevent crosslinking of fibrin and formation of new clots) Coat platelet membranes resulting in decreased platelet function Impairs myometrial contractility
Worsens atonic PPH Low cardiac output and blood pressure = organ perfusion
May be cardiotoxic
Data from 128 women with PPH analyzed Analyzed serial coagulation tests Fibrinogen was the only marker associated with the occurrence of severe PPH
NPV of FG > 4g/L = 79% PPV of FG < 2g/L = 100%
Blood Products
PRBCs
Improve O2 carrying capacity Transfuse based on physical exam, vitals, and ongoing loss Contains all plasma proteins and clotting factors Transfuse if microvascular bleeding from clotting factor deficiency Contains clotting factors and high concentrations of fibrinogen Use if fibrinogen <1.0 g/L and volume status is a concern 1 adult dose should plt count by 25-30 Use if microvascular bleeding and plt count <50
FFP
Cryoprecipitate
Platelets
Ionized Calcium >1.13 mmol/L Urine output >30 cc/hr (>0.5cc/kg/hr) SBP low-normal for age or stability Temperature >35 C pH >7.10 Antifibrinolytics (Cyklokapron)
Produced from
hamster kidney cells Involves extrinsic & intrinsic pathways Results in a thrombin burst to form a strong stable clot at the site of vessel injury
rFVIIa
Approved for use in congenital coagulation
Largest meta-analysis in non-OB cases in 2008 22 RCTs; 3184 patients Reduction in # of blood transfusions (OR 0.54) Possible reduction in mortality (OR 0.88; CI 0.71-1.09) No increased risk of VTE (1% in both groups) Mild increased risk of arterial thrombosis (OR 1.50)
Hsia CC et al. Ann Surg (2008) 248: 61-68.
Risks of rFVIIa
FDAs Adverse Event Reporting System (AERS)
reviewed (1999-2004)
35% in unlabeled indications (most with active bleeding) CVA (39), MI (34), arterial thrombosis (26), PE (32), DVT (42), clotted devices (10) 50 reported deaths (72% due to thromboembolic event)
Registry
9 European countries (2000-2004) Reported use in 128 patients 4 cases of DVT One MI (had cardiac arrest prior to rFVIIa) 27 cases of rFVIIa in obstetrical hemorrhage No adverse effects reported 35 cases No adverse effects reported
Failures attributed to inadequate dosages, unrecognized surgical bleeding, and severe metabolic abnormalities
Adverse events in 2.5% of cases (all thrombotic episodes) Should not be considered a substitute for performing invasive procedures (embolization, conservative surgery) Could consider use before hysterectomy
No reports on safety
SOGC 2009 PPH guidelines Evidence for the benefit of recombinant activated factor VII has been gathered from very few cases of massive PPH. Therefore this agent cannot be recommended as part of routine practice. (II-3L)
Welsh A et al. (2008) Aust NZ J Obstet Gynaecol. 48: 12-16.
sterile water Store at 2-8 C Administer within 3 hours of reconstitution Give as IV bolus over 3-5 minutes Soon coming in vials of 1, 2, & 5 mg at concentration of 1 mg/ml
Reduced risk of blood transfusion (RR 0.61; CI 0.54-0.69) Reduced need for re-operation from bleeding (RR 0.67; CI 0.41-1.09) No increased risk of VTE 461 patients Reduction in PPH incidence (RR 0.4; CI 0.32-0.64) No VTE
currently underway
72 cases
Demographics Average age = 28.1 years Nulliparous = 27 Multiparous = 21 Average gestational age = 35.4 weeks Average stay in hospital = 11.7 days Average pre-pregnancy wt = 65.6 kg 14 cases excluded Miscoded Other coagulopathies Other thrombocytopenias with no coagulation abnormalities
Mode of Delivery
11
Causes of DIC
Abruptio Placentae
#1 = Abruption
38%
3 4
2 18
#2 = PPH
29%
#3 = Preeclampsia
15%
14
Sepsis AFE
PPH Associations
PPH
documented in 38 cases
Causes of PPH
often overlap
PPH Management
Note high rate of emergency hysterectomy (24%)
Surgical Management
3 3 4
Medical Management
19 20
10
Blood Products
PRBCs
0 23 units (avg 7.5) 0 5600 cc 0 20 units (avg 9.5) 0 30 units (avg 11.2) 0 2000 cc Used in 1 case (2 units)
FFP
Cryoprecipitate
Platelets
Albumin
rFVIIa
18 patients Range 1-8 days 3 patients 9 patients (3/9 primiparous) 3 patients (6.25%)
1 fulminant DIC w/ uncontrollable hemorrhage 1 fulminant DIC refusing blood products 1 intracerebral hemorrhage
Emergency Hysterectomy
Maternal mortality
Neonatal Outcomes
4 sets of twins 69% lived 25% died in utero 6% died as neonates 28 NICU admissions Gestational Ages
36
Birthweights
VLBW = 500 -
<1500g
1 infant <500g
LBW = 1500 -
<2500g
Normal = 2500g
and above
17
VLBW
Conclusions
DIC is a rare but serious entity in modern obstetrics High morbidity and mortality (6.25%) DIC is difficult to diagnose and we must have a high
Thank You
QUESTIONS?